Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 15, 2023

SELL
$0.98 - $1.53 $59,584 - $93,024
-60,800 Reduced 29.08%
148,270 $177,000
Q1 2023

May 15, 2023

SELL
$0.96 - $2.92 $864 - $2,628
-900 Reduced 0.43%
209,070 $263,000
Q3 2022

Nov 15, 2022

BUY
$7.21 - $14.88 $1.15 Million - $2.38 Million
160,170 Added 321.63%
209,970 $2.52 Million
Q1 2022

May 13, 2022

BUY
$8.44 - $12.49 $844 - $1,249
100 Added 0.2%
49,800 $432,000
Q3 2021

Nov 10, 2021

SELL
$7.25 - $13.23 $40,600 - $74,088
-5,600 Reduced 10.13%
49,700 $625,000
Q2 2021

Jul 30, 2021

SELL
$8.0 - $9.75 $650,576 - $792,889
-81,322 Reduced 59.52%
55,300 $449,000
Q1 2021

May 06, 2021

SELL
$8.63 - $10.94 $66,451 - $84,238
-7,700 Reduced 5.34%
136,622 $1.26 Million
Q4 2020

Feb 08, 2021

SELL
$8.3 - $13.59 $18 Million - $29.4 Million
-2,163,992 Reduced 93.75%
144,322 $1.4 Million
Q3 2020

Nov 12, 2020

BUY
$11.3 - $14.75 $1.13 Million - $1.47 Million
99,884 Added 4.52%
2,308,314 $28.6 Million
Q2 2020

Aug 13, 2020

BUY
$9.52 - $15.98 $3.54 Million - $5.95 Million
372,055 Added 20.26%
2,208,430 $28.7 Million
Q1 2020

May 14, 2020

BUY
$8.0 - $15.48 $762,960 - $1.48 Million
95,370 Added 5.48%
1,836,375 $18.6 Million
Q4 2019

Feb 18, 2020

SELL
$14.82 - $26.79 $1.34 Million - $2.42 Million
-90,441 Reduced 4.94%
1,741,005 $27.2 Million
Q3 2019

Nov 14, 2019

BUY
$16.02 - $22.47 $3.37 Million - $4.72 Million
210,127 Added 12.96%
1,831,446 $30.8 Million
Q2 2019

Aug 14, 2019

BUY
$16.12 - $22.89 $3.68 Million - $5.23 Million
228,378 Added 16.4%
1,621,319 $36 Million
Q1 2019

May 14, 2019

BUY
$17.58 - $23.97 $24.5 Million - $33.4 Million
1,392,941 New
1,392,941 $30.2 Million

Others Institutions Holding GOSS

About Gossamer Bio, Inc.


  • Ticker GOSS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 93,954,000
  • Market Cap $93M
  • Description
  • Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony...
More about GOSS
Track This Portfolio

Track Alliancebernstein L.P. Portfolio

Follow Alliancebernstein L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alliancebernstein L.P., based on Form 13F filings with the SEC.

News

Stay updated on Alliancebernstein L.P. with notifications on news.